Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
04:27am, Wednesday, 18'th Dec 2024
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
01:39pm, Tuesday, 17'th Dec 2024
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
11:11am, Tuesday, 17'th Dec 2024
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:00am, Tuesday, 17'th Dec 2024
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo's Ozempic faces scrutiny over potential link to rare eye disease
09:49am, Monday, 16'th Dec 2024
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare
Novo Nordisk A/S - share repurchase programme
07:52am, Monday, 16'th Dec 2024
Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Novo Nordisk plans $1.2bn Danish factory investment
03:11am, Monday, 16'th Dec 2024
Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases. In an announcement,
Novo Nordisk to invest $1.2 bln in new plant in Denmark
01:47am, Monday, 16'th Dec 2024
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
01:29am, Monday, 16'th Dec 2024
Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment ma
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
11:53am, Saturday, 14'th Dec 2024
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transacti
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expir
Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip
02:00pm, Friday, 13'th Dec 2024
NVO's reiterated FY2024 guidance and underwhelming FY2025 guidance in "the high teens" imply growth headwinds after the high-double digit growth observed in FY2023. This may be worsened by the uncerta
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
01:31pm, Friday, 13'th Dec 2024
A recent cohort study conducted in Denmark and Norway reveals a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropa
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
09:51am, Friday, 13'th Dec 2024
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
08:32am, Friday, 13'th Dec 2024
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.
